Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Open Label Study of Sequential Taxotere® (Docetaxel) and Gleevec® (Imatinib Mesylate) in Hormone Refractory Prostate Cancer

NCT00861471 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT00861471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00861471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Open Label Study of Sequential Taxotere® (Docetaxel) and Gleevec® (Imatinib Mesylate) in Hormone Refractory Prostate Cancer
Lead sponsor
NYU Langone Health
Phase
Phase 1/2
Overall status
Terminated
Start date
May 31, 2005
Completion date
May 31, 2010
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostatic neoplasms